Analysts See $-0.77 EPS for Myovant Sciences Ltd. (MYOV)

May 17, 2018 - By Betty Noble

Analysts expect Myovant Sciences Ltd. (NYSE:MYOV) to report $-0.77 EPS on June, 13.After having $-0.70 EPS previously, Myovant Sciences Ltd.’s analysts see 10.00 % EPS growth. The stock decreased 2.34% or $0.52 during the last trading session, reaching $21.7. About 48,877 shares traded. Myovant Sciences Ltd. (NYSE:MYOV) has risen 79.46% since May 17, 2017 and is uptrending. It has outperformed by 67.91% the S&P500.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company has market cap of $1.35 billion. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It currently has negative earnings. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction.

Myovant Sciences Ltd. (NYSE:MYOV) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.